// App-Quantinova.ai

: Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Sanfang Tu

Principal Investigators

  • Rui Huang

  • Lan Deng

  • Xuan Zhou

  • Yanjie He

  • Weijun Zhou

  • Jilong Yang

  • Chunyan Yue

  • Anqin Wu

  • Meifang Li

  • Zhenling Guo

  • Lung-Ji Chang

  • Yuhua Li

Medical Centers

  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

  • UESTC, School of Medicine, Chengdu, China

  • Geno-immune Medical Institute, Shenzhen, China

  • Molecular Genetics and Microbioloby, University of Florida, Gainesville, FL

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved